Georges Gemayel - 23 Feb 2026 Form 4 Insider Report for SUPERNUS PHARMACEUTICALS, INC. (SUPN)

Role
Director
Signature
/s/ Timothy C. Dec, as attorney-in-fact
Issuer symbol
SUPN
Transactions as of
23 Feb 2026
Net transactions value
+$194,700
Form type
4
Filing time
25 Feb 2026, 16:36:03 UTC
Previous filing
20 Feb 2026
Next filing
09 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
GEMAYEL GEORGES Director C/O SUPERNUS PHARMACEUTICALS, INC.,, 9715 KEY WEST AVENUE, ROCKVILLE /s/ Timothy C. Dec, as attorney-in-fact 25 Feb 2026 0001256088

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SUPN Common Stock Options Exercise $194,700 +15,000 +80% $12.98 33,684 23 Feb 2026 Direct
transaction SUPN Common Stock Award $0 +4,475 +13% $0.000000 38,159 24 Feb 2026 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SUPN Director Stock Option (Right to Buy) Options Exercise $0 -15,000 -100% $0.000000 0 23 Feb 2026 Common Stock 15,000 $12.98 Direct
transaction SUPN Restricted Stock Unit Disposed to Issuer $0 -4,475 -100% $0.000000 0 24 Feb 2026 Common Stock 4,475 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.
F2 These restricted stock units will be settled in common stock upon vesting, which will occur on February 19, 2026.